PMID- 36135051
OWN - NLM
STAT- MEDLINE
DCOM- 20220923
LR  - 20221020
IS  - 1718-7729 (Electronic)
IS  - 1198-0052 (Print)
IS  - 1198-0052 (Linking)
VI  - 29
IP  - 9
DP  - 2022 Aug 25
TI  - The Efficacy and Safety of Celecoxib in Addition to Standard Cancer Therapy: A 
      Systematic Review and Meta-Analysis of Randomized Controlled Trials.
PG  - 6137-6153
LID - 10.3390/curroncol29090482 [doi]
AB  - The purpose of this meta-analysis was to evaluate the efficacy and safety of 
      celecoxib, a selective cyclooxygenase-2 (COX-2) inhibitor, in addition to 
      standard anticancer therapy. Randomized controlled trials (RCTs) that evaluated 
      the efficacy and safety of celecoxib-combined cancer therapy were systematically 
      searched in PubMed and Embase databases. The endpoints were overall survival 
      (OS), progression-free survival (PFS), disease-free survival (DFS), objective 
      response rate (ORR), disease control rate (DCR), pathological complete response 
      (pCR), and adverse events (AEs). The results of 30 RCTs containing 9655 patients 
      showed limited benefits in celecoxib-combined cancer therapy. However, 
      celecoxib-combined palliative therapy prolonged PFS in epidermal growth factor 
      receptor (EGFR) wild-type patients (HR = 0.57, 95%CI = 0.35-0.94). Moreover, 
      despite a slight increase in thrombocytopenia (RR = 1.35, 95%CI = 1.08-1.69), 
      there was no increase in other toxicities. Celecoxib combined with adjuvant 
      therapy indicated a better OS (HR = 0.850, 95%CI = 0.725-0.996). Furthermore, 
      celecoxib plus neoadjuvant therapy improved the ORR in standard cancer therapy, 
      especially neoadjuvant therapy (overall: RR = 1.13, 95%CI = 1.03-1.23; 
      neoadjuvant therapy: RR = 1.25, 95%CI = 1.09-1.44), but not pCR. Our study 
      indicated that adding celecoxib to palliative therapy prolongs the PFS of EGFR 
      wild-type patients, with good safety profiles. Celecoxib combined with adjuvant 
      therapy prolongs OS, and celecoxib plus neoadjuvant therapy improves the ORR. 
      Thus, celecoxib-combined cancer therapy may be a promising therapy strategy.
FAU - Ye, Shi-Yu
AU  - Ye SY
AD  - Department of Surgical Oncology and General Surgery, The First Hospital of China 
      Medical University, 155 N. Nanjing Street, Shenyang 110002, China.
AD  - Key Laboratory of Precision Diagnosis and Treatment of Gastrointestinal Tumors, 
      Ministry of Education, China Medical University, Shenyang 110122, China.
AD  - Institute of Health Sciences, China Medical University, Shenyang 110122, China.
FAU - Li, Jia-Yi
AU  - Li JY
AD  - Department of Surgical Oncology and General Surgery, The First Hospital of China 
      Medical University, 155 N. Nanjing Street, Shenyang 110002, China.
AD  - Key Laboratory of Precision Diagnosis and Treatment of Gastrointestinal Tumors, 
      Ministry of Education, China Medical University, Shenyang 110122, China.
AD  - Institute of Health Sciences, China Medical University, Shenyang 110122, China.
FAU - Li, Teng-Hui
AU  - Li TH
AD  - Department of Surgical Oncology and General Surgery, The First Hospital of China 
      Medical University, 155 N. Nanjing Street, Shenyang 110002, China.
AD  - Key Laboratory of Precision Diagnosis and Treatment of Gastrointestinal Tumors, 
      Ministry of Education, China Medical University, Shenyang 110122, China.
AD  - Institute of Health Sciences, China Medical University, Shenyang 110122, China.
FAU - Song, Yong-Xi
AU  - Song YX
AD  - Department of Surgical Oncology and General Surgery, The First Hospital of China 
      Medical University, 155 N. Nanjing Street, Shenyang 110002, China.
AD  - Key Laboratory of Precision Diagnosis and Treatment of Gastrointestinal Tumors, 
      Ministry of Education, China Medical University, Shenyang 110122, China.
AD  - Institute of Health Sciences, China Medical University, Shenyang 110122, China.
FAU - Sun, Jing-Xu
AU  - Sun JX
AD  - Department of Surgical Oncology and General Surgery, The First Hospital of China 
      Medical University, 155 N. Nanjing Street, Shenyang 110002, China.
AD  - Key Laboratory of Precision Diagnosis and Treatment of Gastrointestinal Tumors, 
      Ministry of Education, China Medical University, Shenyang 110122, China.
AD  - Institute of Health Sciences, China Medical University, Shenyang 110122, China.
FAU - Chen, Xiao-Wan
AU  - Chen XW
AD  - Department of Surgical Oncology and General Surgery, The First Hospital of China 
      Medical University, 155 N. Nanjing Street, Shenyang 110002, China.
AD  - Key Laboratory of Precision Diagnosis and Treatment of Gastrointestinal Tumors, 
      Ministry of Education, China Medical University, Shenyang 110122, China.
AD  - Institute of Health Sciences, China Medical University, Shenyang 110122, China.
FAU - Zhao, Jun-Hua
AU  - Zhao JH
AD  - Department of Surgical Oncology and General Surgery, The First Hospital of China 
      Medical University, 155 N. Nanjing Street, Shenyang 110002, China.
AD  - Key Laboratory of Precision Diagnosis and Treatment of Gastrointestinal Tumors, 
      Ministry of Education, China Medical University, Shenyang 110122, China.
AD  - Institute of Health Sciences, China Medical University, Shenyang 110122, China.
FAU - Li, Yuan
AU  - Li Y
AD  - Department of Surgical Oncology and General Surgery, The First Hospital of China 
      Medical University, 155 N. Nanjing Street, Shenyang 110002, China.
AD  - Key Laboratory of Precision Diagnosis and Treatment of Gastrointestinal Tumors, 
      Ministry of Education, China Medical University, Shenyang 110122, China.
AD  - Institute of Health Sciences, China Medical University, Shenyang 110122, China.
FAU - Wu, Zhong-Hua
AU  - Wu ZH
AD  - Department of Surgical Oncology and General Surgery, The First Hospital of China 
      Medical University, 155 N. Nanjing Street, Shenyang 110002, China.
AD  - Key Laboratory of Precision Diagnosis and Treatment of Gastrointestinal Tumors, 
      Ministry of Education, China Medical University, Shenyang 110122, China.
AD  - Institute of Health Sciences, China Medical University, Shenyang 110122, China.
FAU - Gao, Peng
AU  - Gao P
AD  - Department of Surgical Oncology and General Surgery, The First Hospital of China 
      Medical University, 155 N. Nanjing Street, Shenyang 110002, China.
AD  - Key Laboratory of Precision Diagnosis and Treatment of Gastrointestinal Tumors, 
      Ministry of Education, China Medical University, Shenyang 110122, China.
AD  - Institute of Health Sciences, China Medical University, Shenyang 110122, China.
FAU - Huang, Xuan-Zhang
AU  - Huang XZ
AD  - Department of Surgical Oncology and General Surgery, The First Hospital of China 
      Medical University, 155 N. Nanjing Street, Shenyang 110002, China.
AD  - Key Laboratory of Precision Diagnosis and Treatment of Gastrointestinal Tumors, 
      Ministry of Education, China Medical University, Shenyang 110122, China.
AD  - Institute of Health Sciences, China Medical University, Shenyang 110122, China.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Research Support, Non-U.S. Gov't
PT  - Review
PT  - Systematic Review
DEP - 20220825
PL  - Switzerland
TA  - Curr Oncol
JT  - Current oncology (Toronto, Ont.)
JID - 9502503
RN  - EC 1.14.99.1 (Cyclooxygenase 2)
RN  - EC 2.7.10.1 (ErbB Receptors)
RN  - JCX84Q7J1L (Celecoxib)
SB  - IM
MH  - *Carcinoma, Non-Small-Cell Lung
MH  - Celecoxib/therapeutic use
MH  - Cyclooxygenase 2
MH  - ErbB Receptors
MH  - Humans
MH  - *Lung Neoplasms
MH  - Randomized Controlled Trials as Topic
PMC - PMC9497539
OTO - NOTNLM
OT  - cancer therapy
OT  - celecoxib
OT  - local control
OT  - meta-analysis
OT  - survival
COIS- The authors declare no conflict of interest.
EDAT- 2022/09/23 06:00
MHDA- 2022/09/24 06:00
PMCR- 2022/08/25
CRDT- 2022/09/22 08:13
PHST- 2022/06/26 00:00 [received]
PHST- 2022/08/20 00:00 [revised]
PHST- 2022/08/23 00:00 [accepted]
PHST- 2022/09/22 08:13 [entrez]
PHST- 2022/09/23 06:00 [pubmed]
PHST- 2022/09/24 06:00 [medline]
PHST- 2022/08/25 00:00 [pmc-release]
AID - curroncol29090482 [pii]
AID - curroncol-29-00482 [pii]
AID - 10.3390/curroncol29090482 [doi]
PST - epublish
SO  - Curr Oncol. 2022 Aug 25;29(9):6137-6153. doi: 10.3390/curroncol29090482.